Intercell USA

This highly innovative biopharmaceutical company specializes in the development of “smart vaccines” which include only the essential ingredients and which stimulate both important elements of the human immune system: T-cells and B-cells.  The Winkenwerder Company has assisted Intercell successfully with its initial entry into the United States of its first product, a new Japanese Encephalitis vaccine, and Winkenwerder is positioned to assist with other novel late-stage development vaccines for traveler’s diarrhea and methicillin-resistant staph aureas (MRSA).  Intercell has products that can have a major impact on public health and Winkenwerder is helping bring these products to the marketplace.